Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma
Evaluation of the Nutritional Supplement Oncoxin-Viusid® in the Treatment of 20 Patients With Cutaneous Melanoma in Stage IIB-IIIA
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
La Habana, Cuba, 10600
- Manuel Fajardo Clinical Surgical University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with histological diagnosis of Malignant Cutaneous Melanoma in stage IIB-IIC-IIIA
- Subjects of 18 years and over of both sexes.
- General health status according to the Karnofsky Index ≥ 70.
- Laboratory parameters within the normal limits defined as: Hematopoietic: Hemoglobin ≥ 9 g / L, Total Leukocytes ≥ 3 x 109 cells / L, Neutrophils ≥ 1.5 x 109 cells / L, Platelets ≥ 100 x 109 / L Hepatic: Liver function within 2.5 times upper normal limit and without liver disease demonstrated by TGP, OGT and alkaline phosphatase.
- Patients who express written voluntariness to enter the study with their signature of the informed consent document.
- Women of childbearing age should have a negative pregnancy test and use effective contraceptive methods such as intrauterine devices, hormonal contraceptives, barrier method or tubal ligation.
Exclusion Criteria:
- Pregnancy or lactation.
- Patients with a second concomitant tumor.
- Present an associated chronic disease in the decompensation phase (heart disease, diabetes, hypertension).
- History of hypersensitivity to another similar product.
- Severe acute allergic states.
- Severe septic processes.
- Non-operated patients, in whom the surgery was contraindicated.
- Patients at potential risk of not completing the study (those who will travel during the period of the investigation or distance in their residence, outside the city).
- Subjects who are participating in another clinical trial.
- Patients with cognitive disorders or a mental disorder that hinders their follow-up.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Oncoxin-Viusid
Nutritional supplement Oncoxin-Viusid 25 mL in oral solution twice a day
|
Oncoxin-Viusid supplement before/during/after standard surgical and adjuvant treatment or chemotherapy.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival rate
Time Frame: 2 years
|
Calculated according to the method of Kaplan Meyer
|
2 years
|
|
Disease free survival rate
Time Frame: 2 years
|
Calculated according to the Kaplan Meyer method
|
2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Temporary interruption of conventional treatment
Time Frame: 2 years
|
Due to adverse events
|
2 years
|
|
Presence of adverse events
Time Frame: 2 years
|
Associated with conventional treatment
|
2 years
|
|
Type of adverse events
Time Frame: 2 years
|
According to severity and causality
|
2 years
|
|
Quality of life
Time Frame: 2 years
|
Quality of life questionnaire of the EORTC: QLQ30
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Olaine R. Gray Lovio, Dr., Manuel Fajardo Clinical Surgical University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- OOS-CANCER-2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.